Galmed Historical Cash Flow
| GLMD Stock | USD 1.59 0.09 5.36% |
Analysis of Galmed Pharmaceuticals cash flow over time is an excellent tool to project Galmed Pharmaceuticals future capital expenditures as well as to predict the amount of cash needed to cover cost of sales, R&D expenses or production expansions. Investors should almost always look for trends in cash flow indicators such as Change In Working Capital of 81.9 K or Begin Period Cash Flow of 2.3 M as it is a great indicator of Galmed Pharmaceuticals ability to facilitate future growth, repay debt on time or pay out dividends.
Financial Statement Analysis is much more than just reviewing and examining Galmed Pharmaceuticals latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Galmed Pharmaceuticals is a good buy for the upcoming year.
Galmed |
About Galmed Cash Flow Analysis
The Cash Flow Statement is a financial statement that shows how changes in Galmed balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which Galmed's non-liquid assets can be easily converted into cash.
Galmed Pharmaceuticals Cash Flow Chart
Add Fundamental
Stock Based Compensation
Compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders.Begin Period Cash Flow
The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.Most accounts from Galmed Pharmaceuticals' cash flow statement are interrelated and interconnected. However, analyzing cash flow statement accounts one by one will only give a small insight into Galmed Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of cash flow statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Galmed Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. For information on how to trade Galmed Stock refer to our How to Trade Galmed Stock guide.At present, Galmed Pharmaceuticals' Change To Account Receivables is projected to increase significantly based on the last few years of reporting. The current year's Investments is expected to grow to about 603.8 K, whereas Stock Based Compensation is forecasted to decline to about 762.7 K.
Galmed Pharmaceuticals cash flow statement Correlations
Click cells to compare fundamentals
Galmed Pharmaceuticals Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Galmed Pharmaceuticals cash flow statement Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Change To Inventory | 609K | (15K) | 313K | (300K) | (345K) | (327.8K) | |
| Change In Cash | (9.0M) | (4.1M) | (868K) | 848K | 763.2K | 801.4K | |
| Stock Based Compensation | 2.1M | 1.9M | 1.3M | 892K | 802.8K | 762.7K | |
| Free Cash Flow | (26.3M) | (32.9M) | (18.5M) | (6.1M) | (5.5M) | (5.8M) | |
| Change In Working Capital | 1.1M | (2.5M) | (2.5M) | 132K | 118.8K | 81.9K | |
| Begin Period Cash Flow | 16.0M | 7.1M | 3.0M | 2.1M | 2.4M | 2.3M | |
| Other Cashflows From Financing Activities | 61K | 11.5M | 17.6M | 800K | 920K | 874K | |
| Depreciation | 35K | 39K | 42K | 31K | 35.7K | 33.9K | |
| Other Non Cash Items | (285K) | 13K | 485K | (280K) | (252K) | (239.4K) | |
| Capital Expenditures | 90K | 12K | 44K | 11K | 4K | 0.0 | |
| Total Cash From Operating Activities | (26.3M) | (32.9M) | (18.5M) | (6.1M) | (5.5M) | (5.8M) | |
| Change To Account Receivables | 15K | (313K) | 300K | 345K | 396.8K | 416.6K | |
| Net Income | (28.8M) | (32.5M) | (17.9M) | (6.9M) | (6.2M) | (6.5M) | |
| Total Cash From Financing Activities | 768K | 17.4M | 70K | 6.2M | 5.6M | 5.3M | |
| End Period Cash Flow | 7.1M | 3.0M | 2.1M | 3.0M | 2.7M | 2.5M | |
| Investments | 16.6M | 11.5M | 17.6M | 500K | 575K | 603.8K | |
| Change To Netincome | 1.7M | 2.1M | 1.3M | 1.8M | 1.6M | 2.2M | |
| Other Cashflows From Investing Activities | 6.7M | 24.9M | (1K) | 17.6K | 20.2K | 21.2K | |
| Issuance Of Capital Stock | 707K | 17.4M | 70K | 6.2M | 5.6M | 5.3M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| ZLAB | Zai Lab | |
| ASLE | AerSale Corp | |
| ATS | AT S Austria |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Galmed Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. For information on how to trade Galmed Stock refer to our How to Trade Galmed Stock guide.You can also try the Fundamental Analysis module to view fundamental data based on most recent published financial statements.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Galmed Pharmaceuticals. If investors know Galmed will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Galmed Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Galmed Pharmaceuticals is measured differently than its book value, which is the value of Galmed that is recorded on the company's balance sheet. Investors also form their own opinion of Galmed Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Galmed Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Galmed Pharmaceuticals' market value can be influenced by many factors that don't directly affect Galmed Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Galmed Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Galmed Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Galmed Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.